Pacific Oaks Med Group [clinicaltrials_resource:621f3d3ae79a6a93507d761b64d8b393]
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients [clinicaltrials:NCT00002234]A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors [clinicaltrials:NCT00002235]The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors [clinicaltrials:NCT00002418]Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment [clinicaltrials:NCT00002419]The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors [clinicaltrials:NCT00002420]A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy [clinicaltrials:NCT00004583]
location [clinicaltrials_vocabulary:location]
Pacific Oaks Med Group [clinicaltrials_resource:621f3d3ae79a6a93507d761b64d8b393]
Bio2RDF identifier
621f3d3ae79a6a93507d761b64d8b393
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:621f3d3ae79a6a93507d761b64d8b393
address [clinicaltrials_vocabulary:address]
identifier
clinicaltrials_resource:621f3d3ae79a6a93507d761b64d8b393
title
Pacific Oaks Med Group
@en
type
label
Pacific Oaks Med Group [clinicaltrials_resource:621f3d3ae79a6a93507d761b64d8b393]
@en